Axela | GenomeWeb


The firms will collaborate on creating and co-marketing array technologies for research and clinical diagnostics.

The partners will work together to develop serological assays measuring antibodies to determine patient immunity to diseases for which vaccines exist.

Axela and Hutman Diagnostics last week announced progress in the co-development of a multiplex pathogen detection system.

Axela and Hutman Diagnostics have announced an agreement that will deliver a microarray-based, sample-to-answer pathogen detection platform to market next year.

NEW YORK (GenomeWeb News) – Axela today announced a development deal to integrate Thermal Gradient's rapid PCR technology into Axela's Flow-Thru Chip automated workflow.

NEW YORK (GenomeWeb News) – Multiplex instrument developer Axela today announced the hiring of investment bank AmeriTech Advisors to explore strategic opportunities for the firm.

Axela and OvaGene Oncology this week announced a partnership that will see OvaGene's gene signatures related to ovarian cancer treatment become available on Axela's Ziplex array platform.

NEW YORK (GenomeWeb News) – Mount Sinai Services in Toronto and Brigham and Women's Hospital in Boston are collaborating to test Axela's Risk of Recurrence Assay, the company said today.

NEW YORK (GenomeWeb News) – Isogen Life Science will distribute Axela's multiplex biomarker platforms in Benelux and Spain under an agreement announced by the firms today.


In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.